Product category:
Clinical chemistry analysis
News Release from: Perkin Elmer LAS (UK) | Subject: Waters Quattro, Quattro Premier
Edited by the Laboratorytalk Editorial
Team on 27 June 2005
Collaboration for advanced neonatal
screening
PerkinElmer will become the exclusive distributor of the Waters Quattro micro and Waters Quattro Premier MS/MS platforms and the Alliance HPLC system for neonatal screening applications
PerkinElmer and Waters have entered a long-term collaboration with a reagent/software/mass spectrometry/liquid chromatography platform to deliver advanced newborn screening solutions PerkinElmer will become the exclusive distributor of the Waters Quattro micro and Waters Quattro Premier MS/MS platforms and the Alliance HPLC system for neonatal screening applications
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
Newborn screening for metabolic disorders has become one of the most widely accepted procedures in preventative pediatrics.
In August 2004, PerkinElmer became the only company in the world to receive clearance from the US Food and Drug Administration for its Neogram tandem mass spectrometry kit (TMS).
It says TMS is helping to drive the global standardisation of metabolic screening with the capability to analyse more than 40 disease markers with a single blood sample.
Early detection increases treatment and management options, leading to an improved quality of life.
PerkinElmer provides a complete screening solution from sample collection to results reporting.
"We are pleased to collaborate with Waters on its mass spectrometry technologies in our integrated solutions for newborn screening," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"Through this agreement, our mutual goal is to ensure a pipeline of advanced and integrated products that protect the health of newborns.
"We are excited about our growth prospects in this area, and remain committed to supporting all existing customer equipment configurations".
"We are excited to deliver our market leading mass spectrometry technologies into the high-growth neonatal screening markets.
"This partnership with PerkinElmer will help speed the development and release of products to enable early intervention and treatment thereby improving the health of newborns, lower healthcare costs and save lives," said Michael Yelle, senior director - clinical business operations at Waters.
""PerkinElmer has broad knowledge and experience in the field of newborn screening, especially in the development and manufacture of reagents and application software, while Waters provides market-leading, high-quality tandem mass spectrometers.".
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
